This week, Quest Diagnostics contracted with the CDC to research the public health impact of hepatitis C; FDA Commissioner Robert Califf published a blog post on clinical trial transparency; Dexcom and Abbott approached a deal in their CGM patent case; and SoClean, Cordis and Eitan all announced recalls.

The $1.1bn acquisition of drug-eluting balloon developer MedAlliance will help Cordis return to its roots as an innovative leader in interventional cardiology.

Restructuring Edition: FibroGen follows its clinical setback with a 32% reduction in force, cutting 104 jobs. Also, Amarin named a new CEO, but cut all US sales and 30% of non-sales US roles, and 9 Meters is headed for dissolution after Chapter 7 bankruptcy, while several others seek strategic alternatives.

Abbott Laboratories moved above Medtronic in MAT medtech revenues, while Philips Healthcare and Stryker finished 2022 with strong quarters, and Roche dropped a few places.